Acquired Lipodystrophy Associated with Nivolumab in a Patient with Advanced Renal Cell Carcinoma.
CONCLUSION: Anti-PD1 therapy has great potential. Early recognition of the onset of unusual collateral effects is important to improve decision making regarding the treatment of patients with tumors.
PMID: 30779841 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Falcao CK, Cabral MCS, Mota JM, Arbache ST, Costa-Riquetto AD, Muniz DQB, Cury-Martins J, Almeida MQ, Cukier Kaczemorska P, Nery M, Teles MG Tags: J Clin Endocrinol Metab Source Type: research
More News: Actos | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Hepatitis | Insulin | Kidney Cancer | Laboratory Medicine | Metformin | Renal Cell Carcinoma